NCT02998047 - A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions

Refractory Multiple Myeloma

Interventions

DRUG

Lintuzumab AC 225

Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer CEnter, New York

53226

Medical College of Wisconsin, Milwaukee

66205

University Of Kansas Medical Center, Kansas City

75246

Baylor Scott and White Research Institute, Charles A. Sammons Cancer Center, Dallas

90095

UCLA, Los Angeles